39520-99-5

Upstream product

• 78347-97-4 (E)-3-styrylthiophene 
• 100-39-0 benzyl bromide 
• 1080-32-6 O,O-diethyl benzylphosphonate 
• 498-62-4 3-thiophene carboxaldehyde 
• 176168-21-1 3-(trimethylsilyl)-4-(phenylethynyl)thiophene 
• 188363-42-0 Trimethyl-(4-phenethyl-thiophen-3-yl)-silane 

Downstream Products

• 21507-85-7 3-(2-phenylethyl)-2-thiophenecarboxylic acid 
• 78347-99-6 2-bromo-3-(2-phenylethyl)thiophene 

Relevant academic research and scientific papers

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Synthetic Applications of 3,4-Bis(trimethylsilyl)thiophene: Unsymmetrically 3,4-Disubstituted Thiophenes and 3.4-Didehydrothiophene

3,4-Bis(trimethylsilyl)thiophene (1a) was synthesized by three routes: (a) 1,3-dipolar cycloaddition; (b) modification of 3,4-dibromothiophene; and (c) intermolecular thiazole-alkyne Diels-Alder reaction. 3,4-Bis(trimethylsilyl)thiophene (1a) can function as a versatile building block for the construction of unsymmetrically 3,4-disubstituted thiophenes utilizing its step wise regiospecific mono-ipso-substitution followed by palladium-catalyzed cross-coupling reactions. In this manner, thiophenes 15, 16, 17a-j, 19a,b, 20, 22a-c, 23a,b, 24a-d, 25a-c, and 27a-j were prepared. The thiophene-3,4-diyl dimer 28 and thiophene-3,4-diyl tetramer 29 were also realized by palladium-catalyzed self-coupling reaction of organoboroxines. The stannylthiophene 31, formed by conversion of the C-Si bond to a C-Sn bond via boroxine 26c underwent both carbonylative coupling and lithiation followed by quenching with electrophiles to afford unsymmetrically 3,4-disubstituted thiophenes 33 and 36a-c as well. Moreover, 3,4-bis(trimethylsilyl)thiophene (1a) can be used as the starting material for the generation of the highly strained cyclic cumulene 3,4-didehy-drothiophene (2), whose existence was substantiated by its trapping reaction with several alkenes.

THIENYL-, FURYL- AND PYRROLYL SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Thienyl-, furyl-and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl) furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: STR1 in which Ar 1 is a 3-or 5-isoxazolyl and Ar. sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar 2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar. sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar 1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET B receptors than the corresponding lower alkyl-substituted compound.

LITHIATION OF SOME 3THIOPHENES AND INTRAMOLECULAR TRANSMETALATION

The reaction of some halo-1-(thienyl)-2-phenylethanes such as 3-(2-phenylethyl)thiophene (1), 3-thiophene (2), 4--2-methylthiophene (3) and 4--2-chlorothiophene (4) with butyllithium and lithium diisopropylamide (LDA) under various conditions has been investigated.Competition between halogen-metal exchange in the benzene ring and metalation of thiophene ring was observed and an intramolecular transmetalation reaction was found.